tradingkey.logo
tradingkey.logo
Search

WAVE Life Sciences Ltd

WVE
Add to Watchlist
6.260USD
+0.420+7.19%
Close 07/02, 13:00ETQuotes delayed by 15 min
1.20BMarket Cap
LossP/E TTM

TradingKey Stock Score of WAVE Life Sciences Ltd

Currency: USD Updated: 2026-07-02

Key Insights

WAVE Life Sciences Ltd's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 36 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 23.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

WAVE Life Sciences Ltd's Score

Industry at a Glance

Industry Ranking
36 / 387
Overall Ranking
111 / 4565
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive

WAVE Life Sciences Ltd Highlights

StrengthsRisks
Wave Life Sciences Ltd. is a biotechnology company focused on unlocking the broad potential of ribonucleic acid (RNA) medicines to transform human health. The Company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities includes editing, splicing, RNA interference and antisense silencing, providing Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. The Company’s diversified pipeline includes clinical programs in alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington’s disease, as well as several preclinical programs utilizing the Company’s broad RNA therapeutics toolkit. Its programs include WVE-006, SERPINA1 (AATD); WVE-007 (GalNAc), INHBE (Obesity); WVE-N531, Exon 53 (DMD), and WVE-003, mHTT (HD).
Growing
The company is in a growing phase, with the latest annual income totaling USD 42.73M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 42.73M.
Overvalued
The company’s latest PE is -5.94, at a high 3-year percentile range.
Held by Lee Ainslie
Star Investor Lee Ainslie holds 11.62M shares of this stock.

Analyst Rating

Based on 16 analysts
Buy
Current Rating
23.000
Target Price
+293.84%
Upside Space

FAQs

How does TradingKey generate the Stock Score of WAVE Life Sciences Ltd?

The TradingKey Stock Score provides a comprehensive assessment of WAVE Life Sciences Ltd based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of WAVE Life Sciences Ltd’s performance and outlook.

How do we generate the financial health score of WAVE Life Sciences Ltd?

To generate the financial health score of WAVE Life Sciences Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects WAVE Life Sciences Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of WAVE Life Sciences Ltd.

How do we generate the company valuation score of WAVE Life Sciences Ltd?

To generate the company valuation score of WAVE Life Sciences Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare WAVE Life Sciences Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of WAVE Life Sciences Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of WAVE Life Sciences Ltd.

How do we generate the earnings forecast score of WAVE Life Sciences Ltd?

To calculate the earnings forecast score of WAVE Life Sciences Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on WAVE Life Sciences Ltd’s future.

How do we generate the price momentum score of WAVE Life Sciences Ltd?

When generating the price momentum score for WAVE Life Sciences Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of WAVE Life Sciences Ltd’s prices. A higher score indicates a more stable short-term price trend for WAVE Life Sciences Ltd.

How do we generate the institutional confidence score of WAVE Life Sciences Ltd?

To generate the institutional confidence score of WAVE Life Sciences Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about WAVE Life Sciences Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of WAVE Life Sciences Ltd.

How do we generate the risk management score of WAVE Life Sciences Ltd?

To assess the risk management score of WAVE Life Sciences Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of WAVE Life Sciences Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of WAVE Life Sciences Ltd.